首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1891001

硬化療法市場：按類型、適應症、給藥途徑、醫療機構和地區分類

Sclerotherapy Market, By Type, By Indication, By Delivery Form, By Care Setting, By Geography

出版日期: 2025年11月09日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2025 年，硬化療法市場價值將達到 12.4 億美元，到 2032 年將達到 18.8 億美元，2025 年至 2032 年的複合年成長率為 6.1%。

報告內容		報告詳情
基準年：	2024	2025年市場規模：	12.4億美元
歷史數據時期：	2020-2024	預測期：	2025-2032
預測期間（2025-2032年）：	6.10%	2032 年的預測值：	18.8億美元

全球硬化療法市場是血管治療這一大領域中的一個重要組成部分，血管治療包括旨在治療各種靜脈疾病（特別是靜脈曲張和蜘蛛網狀靜脈曲張）的微創醫療程序。

硬化療法是將特製的硬化劑直接注射到受損血管中，使其收縮閉合，最終被人體自身的癒合過程吸收。在過去幾十年裡，這種治療方法取得了顯著發展，從傳統的液體硬化劑發展到如今療效更佳、患者預後更佳的先進泡沫製劑。

市面上有多種硬化劑，包括聚多卡醇、十四烷基硫酸鈉和高滲透壓鹽溶液，每種硬化劑都針對特定的血管類型和患者情況而設計。由於久坐的生活方式、肥胖、人口老化和職業風險因素，靜脈功能不全疾病的盛行率不斷上升，這顯著擴大了硬化療法的潛在市場。

此外，人們對美觀的日益關注以及門診治療方案的普及也促進了市場的強勁成長。該市場服務於各種醫療機構，例如專科靜脈診所、皮膚科中心、心血管外科和門診手術中心，這反映出硬化療法作為靜脈疾病的首選治療方法，已被各個醫學專科廣泛採用。

市場動態

全球硬化療法市場受多種強勁因素驅動，在已開發經濟體和新興經濟體均呈現擴張態勢。其中，靜脈疾病盛行率的上升是主要成長要素，全球約有25%的成年人患有靜脈曲張，催生了對有效治療方案的巨大需求。人口老化，尤其是在已開發地區，顯著擴大了市場機遇，因為與老齡化相關的靜脈功能不全日益普遍。

硬化劑製劑技術的進步，特別是微泡沫技術和超音波導引手術的發展，提高了治療的精確度和有效性，同時減少了手術併發症。醫療保健支出的成長，以及醫療必需的硬化療法保險覆蓋範圍的擴大，使得更多患者能夠獲得治療。然而，市場成長仍面臨諸多限制因素，例如嚴格的硬化劑核准法規結構，這可能導致產品上市延遲和研發成本增加。此外，硬化劑可能出現副作用，包括罕見但嚴重的併發症，例如過敏反應、皮膚變色和深層靜脈栓塞症，這些風險也加劇了患者的猶豫和監管機構的審查。

許多醫療體系對美容手術的報銷政策有限，阻礙了市場滲透，尤其是在美容應用領域。此外，來自其他治療方法（如靜脈注射雷射治療、射頻消融和外科手術）的競爭也為市場佔有率擴張帶來了挑戰。然而，發展中市場醫療基礎設施的不斷改善帶來了巨大的機會。可支配收入的增加和對治療方案認知度的提高正在創造尚未開發的市場潛力。新一代硬化劑的研發，憑藉其更高的安全性和更強的療效，為市場成長提供了巨大的潛力。此外，數位健康技術和遠端醫療平台的整合也為患者參與和治療監測開闢了創新途徑。

本次調查的主要特點

本報告對全球硬化療法市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和復合年成長率（%）。
它還重點介紹了各個細分市場的潛在商機，並解釋了該市場具有吸引力的投資提案矩陣。
該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業。
本報告根據以下參數對全球硬化療法市場的主要企業進行了分析：公司概況、產品系列、主要特徵、財務表現和策略。
本報告的研究結果將使負責人和企業經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
這份全球硬化療法市場報告的目標受眾是該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過全球硬化療法市場分析中使用的各種策略矩陣輕鬆做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第9章競爭情勢

Boston Scientific
Merz Pharma
Chemische Fabrik Kreussler & Co. GmbH
Viatris
STD Pharmaceutical Products Ltd
QOL Medical
Omega Laboratories Ltd
Laboratoires Bailleul
Hikma Pharmaceuticals
Leucadia Pharmaceuticals
Teleflex Incorporated
Braun Melsungen AG
Terumo Corporation
Becton, Dickinson and Company
Cook Medical

第10章分析師建議

機會
一致的機會地圖

第11章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI8842

Sclerotherapy Market is estimated to be valued at USD 1.24 Bn in 2025 and is expected to reach USD 1.88 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 1.24 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.10%	2032 Value Projection:	USD 1.88 Bn

The global sclerotherapy market represents a critical segment within the broader vascular treatment landscape, encompassing minimally invasive medical procedures designed to treat various venous disorders, particularly varicose veins and spider veins.

Sclerotherapy involves the injection of specialized sclerosing agents directly into affected blood vessels, causing them to collapse, seal, and eventually be reabsorbed by the body's natural processes. This therapeutic approach has evolved significantly over the past decades, transitioning from traditional liquid sclerosants to advanced foam-based formulations that offer enhanced efficacy and improved patient outcomes.

The market encompasses various sclerosing agents including polidocanol, sodium tetradecyl sulfate, and hypertonic saline solutions, each tailored for specific vessel types and patient conditions. The growing prevalence of venous insufficiency disorders, driven by factors such as sedentary lifestyles, obesity, aging populations, and occupational hazards, has substantially expanded the addressable market for sclerotherapy procedures.

Additionally, increasing awareness about cosmetic appearance and the availability of outpatient treatment options have contributed to the market's robust growth trajectory. The market serves diverse healthcare settings including specialized vein clinics, dermatology centers, cardiovascular surgery departments, and ambulatory surgical centers, reflecting the widespread adoption of sclerotherapy as a preferred treatment modality for venous disorders across various medical specialties.

Market Dynamics

The global sclerotherapy market is propelled by several compelling drivers that collectively fuel its expansion across developed and emerging economies. The primary growth catalyst stems from the escalating prevalence of venous disorders, with approximately 25% of adults worldwide affected by varicose veins, creating substantial demand for effective treatment solutions. Demographic shifts toward aging populations, particularly in developed regions, significantly amplify market opportunities as age-related venous insufficiency becomes increasingly common.

Technological advancements in sclerosing formulations, including the development of microfoam techniques and ultrasound-guided procedures, enhance treatment precision and efficacy while reducing procedural complications. Rising healthcare expenditure, coupled with improved insurance coverage for medically necessary sclerotherapy procedures, facilitates broader patient access to treatment. However, market growth faces notable restraints including stringent regulatory frameworks governing sclerosing agent approvals, which can delay product launches and increase development costs. The risk of adverse reactions, including allergic responses, skin discoloration, and rare but serious complications such as deep vein thrombosis, creates patient hesitancy and regulatory scrutiny.

Limited reimbursement policies for cosmetic procedures in many healthcare systems restrict market penetration, particularly for aesthetic applications. Additionally, competition from alternative treatment modalities including endovenous laser therapy, radiofrequency ablation, and surgical interventions poses challenges to market share expansion. Nevertheless, significant opportunities emerge from expanding healthcare infrastructure in developing markets, where increasing disposable incomes and growing awareness of treatment options create untapped potential. The development of next-generation sclerosing agents with improved safety profiles and enhanced efficacy presents substantial growth prospects, while the integration of digital health technologies and telemedicine platforms offers innovative pathways for patient engagement and treatment monitoring.

Key Features of the Study

This report provides in-depth analysis of the global sclerotherapy market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global sclerotherapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Boston Scientific, Merz Pharma, Chemische Fabrik Kreussler & Co. GmbH, Viatris, STD Pharmaceutical Products Ltd, QOL Medical, Omega Laboratories Ltd, Laboratoires Bailleul, Hikma Pharmaceuticals, Leucadia Pharmaceuticals, Teleflex Incorporated, B. Braun Melsungen AG, Terumo Corporation, Becton, Dickinson and Company, and Cook Medical
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global sclerotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sclerotherapy market

Market Segmentation

Type Insights (Revenue, USD Bn, 2020 - 2032)
- Detergent Sclerosants
- Sodium Tetradecyl Sulfate (STS)
- Polidocanol
- Ethanolamine Oleate
- Others (e.g., Sodium Morrhuate)
- Osmotic Sclerosants
- Hypertonic Saline
- Sclerodex (dextrose/saline solution)
- Chemical Irritants
- Chromated Glycerin
- Polyiodinated Iodine
Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Varicose Veins
- Venous Malformations
- Hemorrhoids
- Hydroceles
- Gastric Varices
- Others (e.g., Esophageal Varices, Cysts)
Delivery Form Insights (Revenue, USD Bn, 2020 - 2032)
- Liquid
- Foam (physician-compounded)
- Packaged microfoam (device-based)
Care Setting Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital outpatient departments
- Ambulatory surgical centers
- Specialty Clinics
- Dermatology/aesthetic clinics
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Boston Scientific
- Merz Pharma
- Chemische Fabrik Kreussler & Co. GmbH
- Viatris
- STD Pharmaceutical Products Ltd
- QOL Medical
- Omega Laboratories Ltd
- Laboratoires Bailleul
- Hikma Pharmaceuticals
- Leucadia Pharmaceuticals
- Teleflex Incorporated
- Braun Melsungen AG
- Terumo Corporation
- Becton, Dickinson and Company
- Cook Medical

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Sclerotherapy Market, By Type
- Global Sclerotherapy Market, By Indication
- Global Sclerotherapy Market, By Delivery Form
- Global Sclerotherapy Market, By Care Setting
- Global Sclerotherapy Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Sclerotherapy Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Detergent Sclerosants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Sodium Tetradecyl Sulfate (STS)
  - Polidocanol
  - Ethanolamine Oleate
  - Others (e.g., Sodium Morrhuate)
Osmotic Sclerosants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Hypertonic Saline
  - Sclerodex (dextrose/saline solution)
Chemical Irritants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Chromated Glycerin
  - Polyiodinated Iodine

5. Global Sclerotherapy Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Varicose Veins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Venous Malformations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hemorrhoids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hydroceles
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Gastric Varices
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (e.g., Esophageal Varices, Cysts)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Sclerotherapy Market, By Delivery Form, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Liquid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Foam (physician-compounded)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Packaged microfoam (device-based)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Sclerotherapy Market, By Care Setting, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital outpatient departments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ambulatory surgical centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Dermatology/aesthetic clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Sclerotherapy Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive landscape

Boston Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merz Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Chemische Fabrik Kreussler & Co. GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
STD Pharmaceutical Products Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
QOL Medical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Omega Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Laboratoires Bailleul
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hikma Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Leucadia Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teleflex Incorporated
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Braun Melsungen AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Terumo Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Becton, Dickinson and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cook Medical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies